Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular EventsEconomic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective

被引：0

作者：

Peter K. Schädlich

Josef Georg Brecht

Badrudin Rangoonwala

Eduard Huppertz

机构：

[1] InForMed GmbH — Outcomes Research and Health Economics,

[2] Bureau Itzehoe,undefined

[3] Aventis Pharma Deutschland GmbH,undefined

来源：

PharmacoEconomics | 2004年 / 22卷

关键词：

Ramipril; Target Variable; Statutory Health Insurance; Heart Outcome Prevention Evaluation; Microvascular Diabetic Complication;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background: In the HOPE (Heart Outcomes Prevention Evaluation) trial, ramipril (compared with placebo) significantly reduced cardiovascular death and all-cause mortality as well as the incidence of costly cardiovascular events, such as myocardial infarction, revascularisation, stroke, cardiac arrest, hospitalisation due to heart failure and worsening angina pectoris, new-onset diabetes mellitus and microvascular diabetic complications.

引用

页码：955 / 973

页数：18

共 50 条

[1] Cost effectiveness of ramipril in patients at high risk for cardiovascular events -: Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective
Schädlich, PK
Brecht, JG
Rangoonwala, B
Huppertz, E
PHARMACOECONOMICS, 2004, 22 (15) : 955 - 973
[2] Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and HypertensionEconomic Evaluation of Ramipril Efficacy In Nephropathy (REIN) Study for Germany from the Perspective of Statutory Health Insurance
Peter K. Schädlich
Josef Georg Brecht
Massimo Brunetti
Eva Pagano
Badrudin Rangoonwala
Eduard Huppertz
PharmacoEconomics, 2001, 19 : 497 - 512
[3] Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension -: Economic evaluation of Ramipril Efficacy In Nephropathy (REIN) study for Germany from the perspective of statutory health insurance
Schädlich, PK
Brecht, JG
Brunetti, M
Pagano, E
Rangoonwala, B
Huppertz, E
PHARMACOECONOMICS, 2001, 19 (05) : 497 - 512
[4] Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial InfarctionEconomic Evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the Perspective of Statutory Health Insurance
Peter K. Schädlich
Eduard Huppertz
Josef Georg Brecht
PharmacoEconomics, 1998, 14 : 653 - 669
[5] Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study
Lamy, A
Yusuf, S
Pogue, J
Gafni, A
CIRCULATION, 2003, 107 (07) : 960 - 965
[6] Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction -: Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the Perspective of Statutory Health Insurance
Schädlich, PK
Huppertz, E
Brecht, JG
PHARMACOECONOMICS, 1998, 14 (06) : 653 - 669
[7] Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the heart outcomes prevention evaluation (HOPE) study
Carroll, CA
Coen, MM
Rymer, MM
CLINICAL THERAPEUTICS, 2003, 25 (04) : 1248 - 1261
[8] Cost effectiveness of ramipril in patients at high risk for cardiovascular events:: a Swiss perspective
Aurbach, A
Russ, W
Battegay, E
Bucher, HC
Brecht, JG
Schädlich, PK
Sendi, P
SWISS MEDICAL WEEKLY, 2004, 134 (27-28) : 399 - 405
[9] Impact of cigarette smoking in patients at high risk of cardiovascular disease. The heart outcomes prevention evaluation (HOPE) Study
Dagenais, GR
Yi, QL
Yusuf, S
CIRCULATION, 2002, 106 (19) : 666 - 666
[10] Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: A Swiss perspective
Sendi, P
Russ, W
Battegay, E
Bucher, H
VALUE IN HEALTH, 2004, 7 (06) : 693 - 693

← 1 2 3 4 5 →